$4.25
+0.30 (+7.59%)
Open$4.10
Previous Close$3.95
Day High$4.27
Day Low$3.98
52W High$31.44
52W Low$15.14
Volume—
Avg Volume553.5K
Market Cap226.24M
P/E Ratio19.24
EPS$1.54
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+650.4% upside
Current
$4.25
$4.25
Target
$31.89
$31.89
$22.93
$31.89 avg
$41.27
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 635.25M | 656.40M | 699.53M |
| Net Income | 12.40M | 10.36M | 12.63M |
| Profit Margin | 2.0% | 1.6% | 1.8% |
| EBITDA | 19.03M | 18.53M | 18.96M |
| Free Cash Flow | 7.11M | 6.70M | 12.14M |
| Rev Growth | +11.6% | +1.9% | +12.9% |
| Debt/Equity | 0.13 | 0.12 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |